9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.520367936925098
- age_years
- 29
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.409
- OXIDATIVE_PHOSPHORYLATION+0.386
- HEDGEHOG_SIGNALING+0.375
- MITOTIC_SPINDLE+0.373
- NOTCH_SIGNALING+0.368
- UV_RESPONSE_DN+0.355
- MTORC1_SIGNALING+0.299
- WNT_BETA_CATENIN_SIGNALING+0.293
- CHOLESTEROL_HOMEOSTASIS+0.269
- UNFOLDED_PROTEIN_RESPONSE+0.247
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.386
- COAGULATION-0.370
- ALLOGRAFT_REJECTION-0.351
- ANGIOGENESIS-0.339
- INTERFERON_GAMMA_RESPONSE-0.327
- INTERFERON_ALPHA_RESPONSE-0.304
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.299
- TNFA_SIGNALING_VIA_NFKB-0.297
- KRAS_SIGNALING_DN-0.250
- MYOGENESIS-0.196
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.942 |
| 2 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.937 |
| 3 | BAA2D0D4-DD8C-4F80-8D37-986AFC578536 | — | — | 0.925 |
| 4 | BB79CABB-0912-4E02-ACD9-82EF3AB8B598 | — | — | 0.909 |
| 5 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.901 |
| 6 | 92A04345-2DCA-49F5-801F-926B59255925 | — | — | 0.898 |
| 7 | 0EF566D2-B40C-4BA1-8314-05AAE647869D | — | — | 0.888 |
| 8 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.888 |
| 9 | DE716AF0-930E-4747-B7FE-4AFAA45212DC | — | — | 0.882 |
| 10 | SRR934798 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.409 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.386 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.375 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.373 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.368 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.355 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.299 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.293 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.269 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.247 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.245 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.241 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.233 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.224 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.221 | Temsirolimus | — uncovered |
| PEROXISOME | 0.196 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.194 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.185 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.177 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.154 | Inavolisib | — uncovered |